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Abstract 
Scaffold proteins play important roles in regulating signalling network fidelity, the absence 
of which is often the basis for diseases such as cancer.   In the present work, we show that 
the prototypical scaffold protein Shc is phosphorylated by the extracellular signal-regulated 
kinase, Erk.  In addition, Shc threonine phosphorylation is specifically up-regulated in two 
selected triple-negative breast cancer (TNBC) cell lines.  To explore how Erk-mediated 
threonine phosphorylation on Shc might play a role in the dysregulation of signalling events, 
we investigated how Shc affects pathways downstream of EGF receptor.  Using an in vitro 
model and biophysical analysis, we show that Shc threonine phosphorylation is responsible 
for elevated Akt and Erk signalling, potentially through the recruitment of the 14-3-3 Ƀ
Pin-1 proteins.    
 
Introduction  
Scaffold proteins play an important role in propagation of signals from cell surface receptors. 
Bringing signalling proteins into proximity on a common structure provides increased 
opportunity for regulation of downstream response through signal specification and 
amplification.  Initiation of signal transduction from receptor tyrosine kinases (RTKs) is 
dominated by tyrosine phosphorylation, however this is often superseded by 
serine/threonine kinase up-regulation.  Juxtaposing of tyrosine and serine/threonine 
cognate binding sites on a scaffold protein provides the opportunity for fine-tuning of RTK 
signal transduction through modulating protein-protein interactions (Deribe et. al., 2010; 
Johnson und Lewis, 2001; Seet et. al., 2006). 
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The prototypical scaffold protein ShcA (henceforth Shc) has been extensively studied in 
regard to its ability to recruit proteins dynamically in RTK-mediated signalling. It plays a 
complex role as a hub for binding of numerous signalling proteins. Despite having no 
intrinsic enzyme activity, Shc is involved in signal transduction associated with poor 
prognosis in breast cancer patients (Ursini-Siegel & Muller, 2008). The ShcA gene encodes 
three isoforms of 46, 52 and 66 kDa (p46, p52 and p66 respectively) which all possess an N-
terminal PTB domain and a C-terminal SH2 domain which sequentially sandwich a CH1 
domain. Shc binds through its phosphotyrosine binding (PTB) domain to tyrosyl phosphates 
on activated RTKs and undergoes a conformational change which exposes its SH2 domain 
(George et. al., 2008). Within the sequence of Shc are a number of tyrosine, serine and 
threonine phosphorylation sites which enable Shc to recruit a large, multi-functional array 
of proteins which appear to be temporally controlled subsequent to RTK activation (Zheng 
et. al., 2013). Shc therefore forms a dynamic hub for protein recruitment.  
 
It has been demonstrated that under non-stimulated conditions Shc (p52Shc) binds directly 
to the proline-directed serine/threonine kinase, Erk (extracellular signal-regulated kinase, 
aka. mitogen-activated protein kinase (MAPK)) (Suen et. al., 2013). In so doing Erk is 
restricted from engaging in MAPK signalling. Erk is released from Shc and becomes up-
regulated in response to RTK-activated MAPK signalling. On activation Erk  phosphorylates 
a wide range of downstream effector protein substrates (Arur et. al., 2009; Carlson et. al., 
2011), including several scaffold proteins, e.g. Grb2-associated binding protein 1 (Gab1) (Gu 
und Neel, 2003; Lehr et. al., 2004; Roshan et. al., 1999; Yu et. al., 2002), fibroblast growth 
factor receptor   ?  ȋ	 ?ȽȌ (Lax et. al., 2002; Wu et. al., 2003) and insulin 
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receptor substrate 1 (IRS1) (Arur et. al.., 2009; De Fea et. al., 1997).  While Shc has recently 
been established to be a substrate for Erk, the significance of these phosphorylation events 
has not been investigated (Zheng et. al., 2013).   Erk-mediated phosphorylation of Shc could 
regulate its ligand binding capability allowing modulation of downstream signalling.  
 
Serine/threonine and tyrosine phosphorylation are considered to be inversely correlated 
events, for example phosphorylation on serine/threonine residues of a scaffold protein 
reduces the level of tyrosine phosphorylation. Since phosphorylated tyrosine residues are 
required to propagate downstream signalling from a RTK, reduction in signalling through 
subsequent serine/threonine phosphorylation results in a negative feedback mechanism for 
pathway control (Lax et. al., 2002; Yu et. al., 2002).  Interestingly, a positive feedback role for 
serine/threonine phosphorylation on scaffold proteins has also been shown.  For example, 
Erk phosphorylation of Gab1 enhances the recruitment of the p85 subunit of 
phosphoinositide 3-kinase (PI3K) to Gab1, resulting in an increase in PI3K and Erk signalling 
(Yu et. al., 2001).   
 
Here we show that three threonine residues on Shc are selectively phosphorylated by Erk in 
vitro and in breast cancer cell lines post-EGF stimulation. Phosphorylation of these residues 
leads to elevated Erk and Akt phosphorylation post-EGF stimulation. We demonstrate how 
phosphorylation on one of these residues appears in two selected triple-negative breast 
cancer cell lines and investigate the structural implications of these phosphorylation events. 
We identify two proteins whose phosphothreonine-dependent association with Shc 
provides evidence for additional downstream signal mediation. 
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Results 
 
Three threonine residues on Shc are substrates for Erk  
Three threonine residues on Shc (T214, T276 and T407) are contained within the Erk 
consensus substrate sequence (S/T-P).  Incubation of purified Shc with active Erk2 in the 
presence of ATP and MgCl2 revealed that Shc is threonine phosphorylated on the putative 
Erk substrate sites (Figure 1A).  Since the commercially available pan-anti-T-P antibody 
cannot distinguish between the three substrate sites for Erk on Shc, we analysed Erk-
phosphorylated, trypsin-digested Shc by mass spectrometry. This showed that three T-P 
motifs on p52Shc were phosphorylated after incubation with Erk (Supplemental Figure 1). 
Of the three sites only T214 has previously been shown to be a substrate for Erk (Zheng et. 
al., 2013). Phosphorylation of T276 on p66Shc by an unknown kinase (Khanday et. al., 2006; 
Rajendran et. al., 2010) has previously been reported.  T214 and T276 are found in the CH1 
domain, whilst T407 is in the SH2 domain (Figure 1B).  Both T214 and T407 are highly 
conserved across various species, whereas T276 is less so (Figure 1C). 
 
Since phosphorylation of Shc has previously been shown to exert regulatory control of ligand 
binding (George et. al., 2008), we investigated whether the phosphorylation of threonine 
residues affected the ability of Shc to bind to a RTK. We expressed and purified a triple 
mutant form of Shc in which the three threonine residues were replaced by the 
phosphorylation charge mimetic of threonine; glutamate (T214/276/407E or TEShc) and 
measured its binding to a known Shc-binding peptide corresponding to the TrkA receptor. 
The mutation of the threonine residues to glutamate mimics the triple phosphorylated state 
of Shc. Isothermal titration calorimetric (ITC) data show that the phosphorylation state of 
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the threonine residues has no effect on recruitment to the receptor demonstrated by the 
comparable dissociation constants for the binding wild type, WTShc, or TEShc to the RTK-
derived peptide (Kd ~ 54nM and 38nM, respectively; Figure 1D).   
 
We previously reported a gating mechanism driven by tyrosine phosphorylation on Shc, 
whereby the SH2 domain is only available for ligand-binding when the CH1 domain is 
phosphorylated on its tyrosine residues (George et. al., 2008).  It has also been proposed that 
phosphorylation on Y317 introduces rigidity to the protein and limits the dynamic motions 
of the PTB and SH2 domains in molecular dynamics simulation studies (Suenaga et. al., 2009, 
2004).  Hence, there is a precedent for regulation imposed by inter-domain interactions.  We 
therefore explored the possibility that threonine phosphorylation induces a conformational 
change in Shc.  The structural model of the full length Shc protein suggests that T214 and 
T276 reside on helices (PDB 1WCP)(Suenaga et. al., 2004).  We therefore employed circular 
dichroism spectroscopy (CD) to investigate the effect of threonine phosphorylation on the 
secondary structure of Shc.  We compared the CD signals from the full length 
unphosphorylated and threonine-phosphorylated Shc.  As expected the CD signal is 
commensurate with the full length Shc protein (ShcFL) containing Ƚ-ǡȾ-strand and 
disordered structure (Supplemental Table 1).  However, no significant changes in the 
structural composition between unphosphorylated and threonine-phosphorylated forms 
were observed as shown by the overlapping signals from the wild type and mutant Shc 
proteins (Figure 1E). A further lack of impact on the protein structure was reflected in the 
thermostability of Shc which was unaffected by threonine phosphorylation Shc (Figure 1F). 
Finally, the similar pattern of protease digestion observed for the WTShc and TEShc proteins 
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(Fontana et. al., 2004) confirmed that no structural variation was imparted by threonine 
phosphorylation (Supplemental Figure 2).  
 
Phosphorylation of T214 is prevalent in triple-negative breast cancer cells 
To investigate the potential pathological relevance of the threonine phosphorylation events 
we screened for the presence of phosphorylation on T214 (pT214) in a number of 
transformed/cancer cell lines with a specific antibody against pT214 (efficiency of antibody 
shown in Supplemental Figure 3).  We initially focused on breast cancer due to the previously 
reported critical role of Shc in this disease (Ursini-Siegel & Muller, 2008) (Figure 2 and 
Supplemental Figure 4).  Non-transformed MCF10A cells (Soule et. al., 1990) were used for 
comparison with the selected cancer cell lines  (Figure 2C).  Cells were stimulated with EGF 
for between 2 and 30 minutes to investigate the temporal pattern of Shc threonine 
phosphorylation.  Cells were also separately pre-incubated with the MAPK/Erk kinase, Mek, 
inhibitor U0126 to abolish Erk activity (Mek is upstream of, and responsible for 
phosphorylation and activation of Erk), in order to confirm that the phosphorylation event 
is mediated by Erk.  We first immunoprecipitated total Shc and then probed for pT214.  
Although all cell lines exhibited Erk activity upon EGF stimulation, only the triple negative 
cell lines MDA-MB-468 and MDA-MB-231 exhibited a significant level of phosphorylation on 
T214 (Figures 2A and 2B).  None of the other cell lines tested showed evidence of 
phosphorylated T214, (i.e. non-transformed MCF10A cells (Figure 2C) and other non-triple 
negative cell lines; MCF7 (Figure 2D), MDA-MB361, A431, HEK293T (Supplemental Figure 
4)).  Two of the known binding partners for Shc in EGF signalling, epidermal growth factor 
receptor, EGFR, and growth factor receptor protein-binding protein 2, Grb2, were probed as 
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controls for Shc function (Figure 2A-D and Supplemental Figure 4). To confirm that Shc is 
threonine phosphorylated in the triple-negative cell lines, we immunoprecipitated Shc using 
the pT214 antibody and then probed for Shc (Figures 2E and 2F). In agreement with the 
previous immunoprecipitation experiments, Shc is phosphorylated on T214 in both MDA-
MB-468 and MDA-MB-231 cells.   
 
It has been reported that serine/threonine phosphorylation affects tyrosine 
phosphorylation in scaffold proteins, so we examined the phosphorylation levels on the 
three known Shc tyrosine sites, 239, 240 and 317 in response to threonine phosphorylation.  
If Shc threonine phosphorylation affects the concomitant tyrosine phosphorylation level, we 
should observe a consistent change in Shc tyrosine phosphorylation when the cells are 
treated with the Mek inhibitor. As expected treatment with U0126 abrogated 
phosphorylation of T214, however the effect on the tyrosine residues across the breast 
cancer cell lines was inconsistent and showed no correlation with the threonine 
phosphorylation observed in triple negative cells (Figure 2A-D). In other words abrogation 
of threonine phosphorylation did not have a uniform effect on tyrosine phosphorylation.  
 
Shc threonine phosphorylation up-regulates Erk and Akt phosphorylation 
Given that Shc is threonine phosphorylated in the metastatic cell lines MDA-MB-468 and 
MDA-MB-231 (Jin et. al., 2012; Kang et. al., 2003; Kathryn et. al., 2012)  but not the non-
transformed MCF10A cells (Debnath et. al., 2003), we hypothesise that Shc threonine 
phosphorylation contributes towards the cellular signalling that is responsible for the 
oncogenic properties reflected in these cell lines.  To test this hypothesis we mutated all 
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three threonine residues (T214/276/407) either to alanine (TAShc: phosphorylation-
deficient mutant) or glutamate residues (TEShc: phosphorylation-mimetic mutant) and 
stably over-expressed these constructs in HEK293T cells.  Both EGFR and Shc regulate 
tumorigenic signalling via the Erk and Akt pathways (Herbst, 2004; Manning & Cantley, 
2007; Roberts & Der, 2007; Ursini-Siegel et. al., 2012; Wills & Jones, 2012), therefore we 
evaluated the phosphorylation levels of Erk and Akt over a time course after EGF stimulation 
in the presence of the mutant forms of Shc.  We found that in cells over-expressing TEShc 
consistently higher levels of Erk phosphorylation across the time course were observed 
compared to WTShc and TAShc over-expressing cells (Figure 3A and 3B).  This suggests that 
the threonine phosphorylation amplifies the level of Erk phosphorylation post-EGF 
stimulation.  Shc therefore functions with Erk in a positive feedback loop in which Erk up-
regulation post growth factor stimulation enhances the potency of its signal through 
phosphorylation of Shc; as has been reported for other scaffold proteins including Gab and 
Frs2 (Lax et. al., 2002; Wu et. al., 2003).  The level of Akt phosphorylation was also seen to 
be affected by the presence of threonine phosphorylation.  We observed a pronounced 
increase in Akt phosphorylation from 2 minutes up until 30 minutes post-EGF stimulation in 
cells overexpressing TEShc compared with cells overexpressing WTShc and TAShc (Figure 3A, 
3C and Supplemental Figure 6).  Therefore a cross-talk mechanism exists between the Erk 
and Akt signalling pathways whereby Erk-mediated phosphorylation of Shc upregulates Akt 
activity.  This is an unexpected result because previous reports suggested that expression of 
the T214A phosphorylation-deficient Shc mutant led to only a moderate increase in cell 
numbers when compared with wild-type Shc (Zheng et. al., 2013), which might be indicative 
of downregulation of proliferative Akt signalling when Shc is threonine phosphorylated.  
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Furthermore, TEShc is able to 1) elicit Akt phosphorylation even in the absence of EGF 
stimulation and 2) sustain Akt phosphorylation for longer than Erk phosphorylation.  Both 
of these observations suggest the primary role of Shc threonine phosphorylation is to 
modulate the Akt pathway.  The relatively mild positive feed-back loop that Shc and Erk 
engage in could be a by-product of the excess Akt activation that led to a delay in Erk 
dephosphorylation, possibly due to limiting common components (Mendoza et al., 2011). 
The fact that TEShc upregulates Akt phosphorylation without the activation of Erk indicates 
that TEShc is able to directly recruit downstream factors that lead to Akt activation.  We note 
that both Erk and Akt phosphorylation levels are similar between WTShc and TAShc cells.  This 
is consistent with the observation that there is no or a very low level of Shc threonine 
phosphorylation in HEK293T cells (Supplemental figure 4C). 
 
Protein recruitment is dependent on threonine phosphorylation of Shc 
A large array of proteins bind to phosphorylated threonines or serines (Seet et. al., 2006; 
Yaffe & Elia, 2001).  We performed a literature search to identify proteins that would be 
potential ligands for Shc after threonine phosphorylation.  We selected three isoforms of the 
scaffold protein 14-3-3 (Fu et. al., 2000), the E3 ubiquitinase, neural precursor cell expressed 
developmentally down-regulated protein 4, Nedd4 (Ingham et. al., 2004) and peptidyl-prolyl 
cis-trans isomerase NIMA-interacting 1, Pin1 (Lu et. al., 2007; Pinton et. al., 2007; Zheng et. 
al., 2013) as possible candidates. 14-3-3 proteins are known to binding to phosphorylated 
threonines and serines, while both Nedd4 and Pin1 contain WW domains that recognize 
either proline-rich or pThr/Ser motifs.  These proteins were over-expressed, isolated and 
immobilized on agarose beads through fusion tags, and used as bait for pull-down 
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experiments. Cell lysates from the MDA-MB- ? ? ?Ǯǯince Shc is 
threonine phosphorylated within 5 minutes of EGF stimulation in these cells (Figure 2A).  
Cells were starved overnight and then stimulated with EGF for 5 minutes.  Erk activity was 
inhibited by the use of the Mek inhibitor U0126 to abolish ErkȂmediated Shc threonine 
phosphorylation.  
 
All proteins tested were able to pull-down Shc (Figure 4).  Nedd4 binds to Shc constitutively, 
which suggests that the interaction is driven by the proline-rich motifs within the CH1 
domain of Shc rather than phosphorylation (Figure 4A).  All three 14-3-3 isoforms could bind 
to threonine phosphorylated Shc in an EGF stimulation-dependent manner although they 
were differentially affected by Erk activity (Figure 4B and 4C).  When Erk activity is inhibited Ƀǡ binding between Shc and 14-3-3ɒ 
and 14-3-3ɂ remained unchanged. 14-3- ?Ƀ-regulate PI3K 
signalling when recruited to Shc (Ursini-Siegel et. al., 2012), it is therefore likely that 
threonine-phosphorylated Shc augments Akt phosphorylation by interacting with 14-3- ?ɃǤ
Finally, Pin1 interacts with Shc when cells are stimulated with EGF and the binding is 
abolished when Erk activity is inhibited.  This is consistent with the fact that Pin1 binding 
and activity are pT/S-dependent.  A C113A mutation in Pin1, which has been identified as 
affecting the isomerase activity without affecting binding to pT (Ranganathan et. al., 1997), 
did not affect its binding to Shc (Figure 4D).  
 
For proteins whose binding to Shc rely on Erk activation and hence indicating a Shc-
threonine-dependent mechanism, we further tested for their ability to interact with the Shc 
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phospho-mimic (TEShc) in HEK293T cells.  Both Pin1 and 14-3-3 Ƀ pulldown with TEShc at a 
higher level than TAShc (Supplemental Figure 7 and 8).  Therefore, we surmise that Pin1 and 
14-3-3 Ƀ bind to threonine phosphorylated Shc.   
 
We used microscale thermophoresis, MST, to measure the binding of 14-3- ?Ƀ
(Supplementary Figure 5A-C) and Pin1 (Supplementary Figure 5D and E) to 
phosphopeptides containing the sequences including and proximal to pT214, pT276 and 
pT407.  Fluorescently-labelled 14-3- ?Ƀ   ?      
phosphothreonine peptides. Although none of the three Shc threonine phosphorylation sites 
include the canonical binding sequence for 14-3- ?Ƀ(Fu et. al., 2000), we detected binding 
between 14-3- ?Ƀ ? ? ?(Kd=9.8µM) and pT407 (Kd=2.1µM). To confirm 14-3- ?Ƀ
able to interact with pT407 within the context of a folded protein domain, we purified Shc 
SH2 domain with a phospho-mimic mutation (T407E; herein referred to as SH2TE) and 
measured the binding.  In agreement with the peptide data, 14-3- ?Ƀ SH2TE with 
a similar affinity as with pT407 (Kd=1.9µM; Supplementary Figure 5F). Unlike 14-3- ?Ƀ, Pin1 
appears to show a preference for the pT407 (Kd=39µM) over the pT214 (Kd=575µM) 
peptides, suggesting that the sequences flanking the pT contribute to the binding affinity for 
the two proteins.   
  
Discussion 
In this investigation we demonstrate that the role of Shc in signal transduction is greater 
than just  Ǯǯ Ǥ         
downstream effectors Shc can modulate signalling response.  Upon activation of EGFR, Erk 
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phosphorylates Shc on three residues resulting in up-regulation of a positive feedback loop 
in Erk-signalling and crosstalk between the Erk and Akt pathways (Figure 5). Up-regulation 
of proliferative signalling events relate to the finding that a significant level of 
phosphorylation of T214 in two triple-negative breast cancer cell lines, MDA-MB-468 and 
MDA-MB-231, but not in the non-transformed MCF10A cell line.   It is interesting to note that 
while Erk can be phosphorylated in all of the tested cell lines, only the two TNBC cell lines 
exhibit detectable Erk-dependent Shc T214 phosphorylation.  One reason could be that these 
cell lines may engage slightly different protein components downstream of EGF receptor 
activation.  For example, the serine/threonine phosphatase PP2A, which has been shown to 
interact with Shc, is downregulated in breast cancer cells (Seshacharyulu et al., 2013).   It is 
possible that the activity of PP2A is higher in certain cell lines and therefore 
dephosphorylation of the pathways occur more quickly and Shc T214 phosphorylation is 
thus too transient to be captured in our experimental setup.   Indeed, it has been shown that 
in MDA-MB-231, but not MCF7, cells that PP2A is inactivated by the over-expression of its 
inhibitor CIP2A and that tamoxifen treatment leads to the activation of PP2A and 
downregulation of Akt phosphorylation (Liu et. al.., 2014).  
 
Threonine phosphorylation does not appear to induce any structural perturbation (as has 
been observed on tyrosine phosphorylation (George et. al., 2008)) even though two of the 
residues are in the intrinsically disordered CH1 domain.  However, the formation of these 
new phospho-motifs alter protein recruitment.  We identified two proteins, Pin1 and 14-3-
3Ƀ whose binding to Shc is pT-dependent.  Previous reports show that 14-3- ?Ƀ
SH2 domain of Shc is mediated by the phosphorylation of 14-3- ?Ƀon tyrosine 179 which 
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leads to upregulation of PI3K and subsequently Akt signalling (Barry et. al., 2009; Ursini-
Siegel et. al., 2012).  Our data suggest an additional mechanism for this interaction whereby 
14-3-3Ƀ     Ǥ Recruitment of 14-3-3Ƀ    
shown to increase PI3K signalling (Ursini-Siegel et. al., 2012).  Given that PI3K is an upstream 
activator of Akt, it seems likely that this interaction is at least partially responsible for the 
elevated pAkt level seen in TEShc cells (Vanhaesebroeck et. al., 2012).   
 
Pin 1 isomerizes only phospho-serine/threonine-proline motifs and plays a role as a post-
phosphorylation regulator of protein function and hence is implicated in cancer. Pin1 has 
previously been shown to recruit p66Shc to the mitochondria in a PKC-dependent manner, 
which is a process that leads to apoptosis (Pinton et. al., 2007).  Here we show that p52Shc 
can also bind to Pin1, albeit through different phosphothreonine residues.  Some peptide 
prolyl cis-trans isomerases (PPIases), such as Pin1 specifically catalyse isomerisation of 
prolines preceded by pS/pT.  PPIases catalyse the conversion of the cis-trans conformation 
of proline which can potentially switch local conformations from one to another (Lu & Zhou, 
2007) and adjust protein-recruitment profiles.  In addition, because some phosphatases, 
such as PP2A, only act on certain phospho-isoforms, proline-isomerization can also alter the 
rate of phosphorylation/dephosphorylation (Lu & Zhou, 2007; Zhou et. al., 2000). We have 
previously identified another PPIase, cyclophilin A (CypA) as a direct binding partner for Shc 
(George et. al., 2009).  Given that the CH1 domain is proline-rich, there is a strong possibility 
that proline isomerization provides an additional mode of regulation.  
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Finally, in light of the finding that the level of Shc threonine phosphorylation is higher in two 
TNBC cell lines, the Shc threonine phosphorylation sites could potentially serve as markers 
for a subtype of TNBC.  The two TNBC cell lines in which we found pT214 to be significantly 
phosphorylated exhibit over-expression of EGFR and mutant KRAS expression (Kathryn et. 
al., 2012; Kenny et. al., 2007). While TNBC describes a collection of disease states with highly 
variable genotypes, some can be classified in sub-groups by other markers, such as  their 
EGFR expression status (Ferraro et. al., 2013; Park et. al., 2014). If this threonine 
phosphorylation effect is reproduced in other TNBC this could provide a viable basis for 
biomarker development. 
 
Materials and Methods 
 
Reagents 
Antibodies for pErk (4695), Erk (4377), pT308Akt (4056), Akt (4691), pT-P (9391), 
pY239/240Shc (2434), EGFR (2646), GST (2625), 14-3-3 (8312) were obtained from Cell 
Signaling Technology; pY317 (sc-23765R), HA-tag (sc-805), GFP (sc-9996) were obtained 
from Santa Cruz; Shc (MAB0807) and Strep-tag (PAB-16601) was obtained from Abnova.  
The custom antibody for pT214 Shc was generated against peptide NPPKLVpTPHDRMAG by 
Genscript.  Lysis buffer: 50mM HEPES, pH7.5, 50mM NaCl, 1mM EGTA, 10% (w/v) Glycerol, 
1mM Sodium orthovanadate, 10mM Sodium fluoride, 0.1% NP-40, 1x protease and 
phosphoSTOP inhibitors (Roche).  Shc phosphothreonine peptides (pT214: 
CNPPKLVpTPHDRMAG; pT276: CARPTAPNAQpTPSHL; pT407: CDFLVRESTTpTPGQ were 
purchased from Genescript.   
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Mammalian cell culture 
HEK293T, MCF7, MDA-MB-468, MDA-MB-231, A431, PC12 cells were maintained as 
described previously (Suen et. al., 2013); MDA-MB-361 cells was grown in DMEM/F12 
supplemented with 10% FBS.  MCF10A cells were grown as previously described (Debnath 
et. al., 2003).  Transfection HEK293T cells and generation stable cell lines were described 
previously(Suen et. al., 2013). 
Molecular biology 
TAShc and TEShc mutants were generated by site-mutagenesis.  The following constructs were 
obtained from Addgene: GST-tagged 14-3-3 ɂ (13279), GST-tagged 14-3-3 ɒ(13281), and 14-
3-3 Ƀ (mouse; 1942), GST-Pin1 (19027), HA-Nedd4 (27002), His-tagged Pin1 (40773).  A 
mutation of P112A was made in mouse 14-3-3 zeta to match the human sequence and was 
then subcloned into the pEGFP-N vector.  C113A mutation was made in GST-Pin1 by site-
directed mutagenesis. 
In vitro Erk2 phosphorylation of full length Shc (ShcFL) 
 ? ?Ɋ ? ?Ɋ	  ?Ɋ ?ȋǡ
P6080) in the presence of 5mM buffered ATP and 10mM MgCl2 overnight.  
Protein expression and purification 
To express and purify GFP-14-3-3 and HA-Nedd4, HEK293T cells were transfected with 20 
ug of GFP-N-14-3- ?Ƀ ? ?-dish.  2x 10cm-dishes were used per pull-down 
experiment.  Cells were harvested and lysed in 1ml of lysis buffer 48hrs after transfection.    
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Cleared lysates was incubated with 50ul GFP-trap beads overnight.  Beads were washed with 
1ml lysis buffer 5-10 times.   Recombinant his-tagged Shc was expressed and purified as 
described previously (George et. al., 2008).  Phosphorylated his-tagged Shc was purified with 
the additional step of IMAC to remove active Erk2.  GST-tagged proteins and His-tagged Pin1 
were expressed in Rosetta 2.  Bacterial culture was inoculated with overnight culture in 
1:1000 ratio and grown to OD600 0.8 at 37oC.  The temperature was then reduced to 20oC and 
induced with 0.1mM IPTG for overnight.  His-tagged Pin1 was purified first by affinity 
chromatography, followed by a size exclusion step to exchange into final buffers.  GST-tagged 
proteins were immobilized on glutathione-sepharose resins and washed extensively in 
50mM Tris pH8.0, 150mM NaCl and 0.1% Triton-X100.  GST-proteins were then stored at -
20 in 50% glycerol until required. 
Pull-down experiments 
Purified proteins immobilized on beads were incubated with MDA-MB-468 cell lysates 
overnight.  500ug of lysates were used per pull-down.  Samples were then washed in 3x1ml 
lysis buffer and then boiled in Laemmli buffer before analysed by SDS-PAGE and western 
blotting. 
Immunoprecipitation 
Cells were lysed in lysis buffer (typically 1ml of lysis buffer was used on a 10cm-dish) and 
cleared by centrifugation. One milligram of lysate was used per IP experiment.  IP antibody 
was added to the lysate and incubated for overnight.  25 µl of Protein A/G slurry was added 
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to the lysate for 2 h.  The immunoprecipitants were washed three times with lysis buffer and 
boiled with 2× sample buffer for 5 min to elute.  
 
Isothermal titration calorimetry, ITC, experiment 
Experiments were performed using the VP instrument (GE, Northampton, MA) at 13 °C in 20 ǡ ?Ǥ ?ǡ ? ?ǡ ? ?ȾǤ
for heats of dilution. ORIGIN7 software was used for data analysis using the single site model.   
Microscale thermophoresis, MST, experiment 
Ǥǡ ? ?Ɋ ? ? ?ɊǤ ? ?Ɋ-647 was added to the diluted 
protein and incubated for 2-4hrs at room temperature.  ShcPTB was then separated from the 
free dye using a G25-sephadex column in PBS.  Labeling efficiency was typically between 
50%-100%.  To test binding between ShcPTB and ligands, a 1:2 dilution series of each ligand  ? ?ɊǤExperiments were carried out at 25oC. 
Circular dichroism, CD, spectroscopy 
All CD spectra were recorded at room temperature a Jasco J-810 spectropolarimeter in PBS.  
Data was collected at 0.2nm intervals in triplicates.   
Differential scanning fluorescence analysis 
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 ?Ɋ	 proteins were incubated with 1:2000 SYPRO Orange dye dilution (Invitrogen) to 
a final volume of 2 ?Ɋ   ?oC for 20 minutes.  Melting assay was performed on Roche 
LightCycler 480 instrument by applying ROX filter for the fluorescence emission (610 nm) 
and FAM filter for the fluorescence excitation (492 nm). Fluorescence was monitored 
between 20oC and 95oC.  Fluorescence signals from the fully folded and unfolded states were 
plotted as 0% (fully folded) to 100% (fully unfolded).      
 
Limited proteolysis 
100ng of ShcFL proteins were incubated with 0.5ng of chymotrypsin in PBS at 37oC for each 
time point.  Digestion process was terminated by the addition of 2X loading sample buffer 
and boiling for 5min.   
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Figure Legends 
Figure 1: Identification of Erk phosphorylation sites on p52Shc.  (A) Phosphorylation of 
Shc on Erk substrate motifs (T-P)  ? ?Ɋ ? ?Ɋ  ?Ɋ
of active Erk2 in the presence or absence of ATP and MgCl2 for the indicated time periods.  
Phosphorylation of T-P motifs on Shc was analyzed by western blotting using an antibody 
specific to pT-P motifs.  (B) Location of the threonine residues on Shc phosphorylated by Erk.  
Three threonine residues on Shc are phosphorylated by Erk: T214 and T276 are in the CH1 
domain; T407 is in the SH2 domain. (C) Sequence alignment of ShcA from various species 
show that T214, T276 and T407 are conserved.  Hs: Homo sapiens; Mm: Mus musculus; Rn: 
Rattus norvegicus; Gg: Gallus gallus; Xl: Xenopus laevis; Ce: Caenorhabditis elegans.  (D) ITC 
measurement of intact WTShc and TEShc binding to TrkA phosphopeptide. Twenty 10µl 
injections of tyrosyl phosphorylated TrkA peptide (100µM) were titrated into wild type full 
length WTShc or glutamine triple mutant TEShc (10µM) at 13oC. Top panel: baseline-corrected 
power versus time plot for the titration. Bottom panel: the integrated heats and the molar 
ratio of TrkA binding to ShcFL. The data were corrected for the heats of dilution of TrkA and 
fit to a one-site binding model.  Left: WTShcFL; Right: TEShcFL.  Titrations were fitted into a 
one-site model.  KD for WTShc and TEShc are 53nM±435nM and 38nM±427nM, respectively.  
(E) CD spectral analysis of ShcFL proteins.  The average of three scans at 0.5nm intervals for 
each sample is plotted.  Experiments were carried out at room temperature in PBS.  Grey  ǣ  ?Ɋ  Ǣ  ǣ  ?Ɋ  
Shc.  Data was subtracted from the buffer signal and plotted on Excel. (F) DSF analysis of the 
thermostability of ShcFL proteins.   ?Ɋ  unphosphorylated ShcFL and threonine 
phosphorylated ShcFL in PBS were incubated with 1x Sypro orange dye and heated from 
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room temperature to 95oC.  Unfolding of proteins was monitored by increase in fluorescence  Ǥ 
 ǣ  ?ɊǢǣ ?ɊShc. 
Figure 2: Phosphorylation of T214 in endogenous Shc in mammalian cell lines.  Cells 
were starved overnight and then stimulated with 20ng/ml EGF for the indicated time 
periods.  The Mek   ? ? ? ?     ? ?Ɋ   ? ?   
	Ǯ ? ?ǯǤ(A) Ȃ (D) Shc was immunoprecipitated from 1mg of lysates.  
Immunoprecipitants (IP) were probed for pT214 (arrowheads; * denotes non-specific IgG 
heavy-chain bands) and pY239/240 levels of Shc, the presence of EGFR and Grb2.  Whole cell 
lysates (w.c.l.) of the same samples were also analyzed for pErk level and pY317 of Shc.  (A) 
MDA-MB-468 (B) MDA-MB-231 (C) MCF10A  (D) MCF7.  (E) Ȃ (F)   Anti-pT214 antibody was 
used to immunoprecipitate Shc from 1mg of lysates.  Immunoprecipitants (IP) were probed 
total Shc.  (E) MDA-MB-468  (F) MDA-MB-231. 
 
Figure 3: Shc threonine phospho-mimic mutant leads to elevated pAkt and pErk levels.  
(A) HEK293T cells stably overexpressing either empty vector, strep-tagged WTShc, TAShc or 
TEShc were starved overnight and then stimulated with 20ng/ml EGF for the indicated time Ǥ ? ?Ɋ
states of Akt T308 (upper panels) and Erk (middle panels).  Equal expression of the Shc 
constructs were confirmed by blotting for strep-tag (bottom panel).  (B) Phospho-Erk 
response is normalized against loading and fold-change is expressed as proportion of 
response from TEShc at 5min time-point.  (C)Phospho-Akt (308) response is normalized 
against loading and fold-change is expressed as proportion of response from TEShc at 5min 
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time-point.  (B) and (C) Immunoblot bands were quantified by Image J from at least 3 
biological repeats.  Error bars are standard errors.  Blue: WTShc ; Red: TAShc ; Blue: TEShc 
 
Figure 4: Pull-down experiments to identify Shc protein binding partners that are 
affected by Shc threonine phosphorylation.   (A) - (D) Fusion proteins were purified and 
immobilized on agarose beads and incubated with MDA-MB-468 lysates overnight.  Beads 
were washed with lysis buffer and the samples were analyzed by western blotting for the 
presence of Shc.  (A) HA-tagged Nedd4 (B) GFP-14-3- ?ɃȋC) GST-14-3- ?ɒ and GST 14-3- ?ɂ
(D) GST-Pin1 WT or C113A.  
 
Figure 5 Schematic summary of the mutual regulation between Shc and Erk.   In the 
absence of extracellular stimulation to EGFR (green), Shc (blue) and Erk (magenta) form a 
complex in the cytoplasm which inhibits up-regulation of Erk by Mek (Suen et al 2013).  Upon 
EGF stimulation, Shc binds to the activated EGFR, which triggers a conformational change in 
Shc and leads to Erk dissociation from the complex.  Shc is phosphorylated by the receptor 
(red arrows) on its tyrosine residues (green circles/yellow outline), which recruits the Grb2 
(red)-Sos (olive green) complex to the membrance.  This activates Ras, which initiates the 
activation of the Erk cascade (purple arrow).  Activated Erk phosphorylates Shc (blue arrow) 
on threonine residues (cyan circles/blue outline), which further elevates the Erk 
phosphorylation and activates Akt, possibly through the recruitment of 14-3-3 zeta-p85 
complex (including p85 subunit of PI3K (brown)).    
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Supplemental Figures: 
Figure 1: Mass Spectrometry analysis of phosphorylation status of Shc TP motifs.   ? ?Ɋ
of purified  ? ? ?Ɋ ? ?Ɋ ?2 and 
ATP for 16h at 20 oC.  The mass spectra for (A) T214 (B) T276 and (C) T417.  Mass 
spectrometry measurements and analysis were performed by the MDACC core.  (D) 
Sequences of Erk-mediated phosphorylation on Shc. 
 
Figure 2: Limited proteolysis analysis of ShcFL proteins.  100ng of WTShc or TEShc was 
incubated with 1ng of chymotrypsin at 37oC for various periods of time as indicated.  
Samples were analyzed by SDS-PAGE, followed by silver staining.   
 
Figure 3: Specificity test for anti-pT214 antibody.  Purified recombinant Shc was 
phosphorylated by active Erk2.  A western blot signal is only present when Shc was 
phosphorylated by Erk2.  This confirms that the anti-pT214 antibody is specific for 
phosphorylated Shc. 
 
Figure 4:  Phosphorylation of T214 in endogenous Shc in mammalian cell lines.  Cells 
were starved overnight and then stimulated with 20ng/ml EGF for the indicated time Ǥ      ? ? ? ?     ? ?Ɋ   ? ?    
	  Ǯ ? ?ǯ Ǥ       ?  Ǥ
Immunoprecipitants (IP) were probed for pT214 and pY239/240 levels of Shc, the presence 
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of EGFR and Grb2.  Whole cell lysates (w.c.l.) of the same samples were also analyzed for 
pErk level and pY317 of Shc.  (A) MDA-MB-361 (B) A431 (C) HEK293T.   (D) Ȃ (E) Anti-pT214 
antibody was used to immunoprecipitate threonine phosphorylated Shc from lysates.  
Immunoprecipitants (IP) were probed total Shc.  (D) MCF10A  (E) MCF-7. 
 
Figure 5: Biophysical analysis of 14-3- ?Ƀ ?Ǥ
Purified recombinant 14-3- ?Ƀ ?-647 dye.  The 
labeled proteins were incubated with the indicated ligands and fluorescence was monitored.  
The binding curves were fitted by the law of mass action.  (A) 14-3- ?Ƀth pT276   (B) 14-
3- ?Ƀ ? ? ?ȋȌ ? ?-3- ?Ƀ ?TE   (D) Pin1 with pT214   (E) Pin1 with pT407   
(F) Table with fitted KD.   
 
Figure 6: Shc threonine phospho-mimic mutant leads to elevated pAkt 473.   HEK293T 
cells stably overexpressing either strep-tagged WTShc, TAShc or TEShc were starved overnight 
and then stimulated with 20ng/ml EGF for 5 min.  Total cell lysates were analyzed by western 
blotting for the phosphorylation states of Akt T473. 
 
Figure 7: Pin1 interacts with ShcTE mutant in HEK293T cells.  Purified recombinant Pin1 
WT protein fused with GST was incubated with lysates from HEK293T cells overexpressing 
either strep-tagged WTShc, TAShc or TEShc.  Cells were starved overnight and stimulated with 
20ng/ml of EGF for 5min.  To assess interaction between Shc mutants and Pin1, samples 
were analysed by western blotting for the presence of strep-tagged Shc. 
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Figure 8: 14-3-3 Ƀ ? ? ?Ǥ  GFP or GFP-tagged 14-
3-3 Ƀ was transiently expressed in HEK293T cells stably overexpressing either strep-tagged 
WTShc, TAShc or TEShc.  Cells were starved overnight and stimulated with 20ng/ml of EGF for 
5min.  To assess interaction between Shc mutants and 14-3-3 Ƀ, samples were analysed by 
western blotting for the presence of strep-tagged Shc. 
 
 
 
Table 1: Composition of Shc proteins secondary structures derived from CD spectra.  
Analysis of the CD signals from ShcFL proteins was analyzed by the CDSSTR software 
(Fontana et. al., 2004)Ǥ  	     Ƚ-helices, Ⱦ-strand, turns and 
disordered regions.  Both WTShc and TEShc have similar compositions. 
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